Retatrutide dosing schedule
> Updated:
Human schedule
Retatrutide is a triple receptor agonist (GIP/GLP-1/glucagon) administered as a once-weekly subcutaneous injection in studies. Below is a commonly used practical dose-escalation schedule, following the same titration principle clinical trials of this drug class use.
This is a concise reference to regimens described for adults; it is not an individual prescription.
Retatrutide dosing always runs through titration rather than a fixed target dose from week one, so the schedule below shows the escalation sequence, not a single number.
| Period / condition | Dose | Escalation |
|---|---|---|
| Start (weeks 1–4) | 2.5 mg once weekly subcutaneously | Starting dose |
| Titration (every 4 weeks) | 5 → 10 mg once weekly | Increase if needed |
| Upper bound of this schedule | 15 mg once weekly | Maximum in this schedule |
Practical dosing and effect details
In the Phase 2 obesity trial (Jastreboff and colleagues, New England Journal of Medicine, 2023), retatrutide was given as a once-weekly subcutaneous injection, titrated every 4 weeks up to one of several target doses (including 4, 8, and 12 mg) rather than jumping straight to the maximum.
In that trial, higher maintenance doses produced greater average weight reduction at 24 and 48 weeks than lower ones, meaning the effect kept rising with dose across the studied range rather than plateauing right after the start.
The schedule on this page (2.5 mg start, titration to 5→10 mg, 15 mg maximum once weekly) is a commonly used practical version of the same approach: gradual dose escalation over several weeks rather than an immediate target dose. The exact doses tested in the Jastreboff trial itself (4, 8, and 12 mg) differ from this practical schedule, but the titration logic and the interval between increases are the same. A 4-week step between increases is typical for receptor agonists in this class (GIP/GLP-1/glucagon): the interval gives time to assess gastrointestinal tolerability before the next step, not just to reach a target blood concentration.
This is reference information drawn from a published trial and common usage practice, not a medical recommendation and not instructions for self-administration.
This reference is research-use material. The information is not medical advice and is not intended for diagnosis, treatment or prevention of disease.